← Back to Clinical Trials
RecruitingNCT06419101

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionBiomarkers
SponsorCuibai Wei,Clinical Professor
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment3,000
SexALL
Min Age40 Years
Max Age90 Years
Start Date2024-05-30
Completion2034-05-10
All Conditions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Dementia is a syndrome characterized by progressive global cognitive impairment that impairs occupational, family, or social functioning. It detrimentally affects personal health and quality of life, imposing significant medical economy, social and psychological burden on the countries and the patients' family. The internationally renowned dementia cohort includes the DIAN that focused on genetics studies, the ADNI cohort featuring imaging and the FINGERS cohort focused on risk factor intervention, etc. Establishing standardized and shared longitudinal follow-up dementia cohorts and clinical database is an essential challenge for constructing dementia cohort in China. Moreover, there is a lack of large-scale prospective longitudinal follow-up cohorts within the Chinese population that cover subjective cognitive decline (SCD) to explore biomarkers with diagnostic and early warning value for different kinds of dementia and pre-dementia stages. The study will rely on the dementia cohort based on Chinese population to explore the biological phenotype characteristics of the pre-dementia stage and different dementia subtypes, and observe the dynamic change rules of the dementia cohort vertically, so as to foster early intervention and improve prognosis for individuals with dementia.

Eligibility Criteria

Inclusion Criteria: * Male or female patients aged ≥40 and ≤90years; * Chief complaint or others describe a cognitive decline; * Ability to communicate in Chinese; * The patients and their families were informed and signed the informed consent. Exclusion Criteria: * MMSE\<10; * There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.); * There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); * Suffering from a disease that cannot cooperate with the completion of cognitive examination; * There are contraindications to nuclear magnetic resonance; * There is mental and neurodevelopment

Related Trials